250 related articles for article (PubMed ID: 17064987)
41. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
42. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
43. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
44. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies.
Georgii A; Buhr T; Buesche G; Kreft A; Choritz H
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():15-29. PubMed ID: 8951769
[TBL] [Abstract][Full Text] [Related]
45. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
46. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
47. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Ann Hematol; 2001 Mar; 80(3):160-5. PubMed ID: 11320901
[TBL] [Abstract][Full Text] [Related]
48. Prodromal myeloproliferative neoplasms: the 2008 WHO classification.
Kvasnicka HM; Thiele J
Am J Hematol; 2010 Jan; 85(1):62-9. PubMed ID: 19844986
[TBL] [Abstract][Full Text] [Related]
49. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
50. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
51. Myelofibrosis in chronic myeloproliferative disorders--dynamics and clinical impact.
Thiele J; Kvasnicka HM
Histol Histopathol; 2006 Dec; 21(12):1367-78. PubMed ID: 16977587
[TBL] [Abstract][Full Text] [Related]
52. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
[TBL] [Abstract][Full Text] [Related]
53. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2001 Apr; 86(4):368-74. PubMed ID: 11325641
[TBL] [Abstract][Full Text] [Related]
54. Patho-anatomical features of the bone marrow.
Lennert K; Nagai K; Schwarze EW
Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
[No Abstract] [Full Text] [Related]
55. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
[TBL] [Abstract][Full Text] [Related]
56. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
57. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
59. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Leuk Lymphoma; 2006 Mar; 47(3):381-96. PubMed ID: 16396760
[TBL] [Abstract][Full Text] [Related]
60. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]